Lung Cancer, Non-Small Cell research hub
7 indexed studies · 4 currently recruiting
- recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum Based Chemotherapy with Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL 1L)
This study looks at a new combination treatment for advanced lung cancer (non-small cell lung cancer). It compares two medicines, Niraparib and Pembrolizumab, with Pembrolizumab alone, to see if the combination helps people live longer or keeps their cancer from growing for longer.
Netherlands · Poland · Hungary - recruitingTherapeutic exploratory (Phase II)
A RANDOMIZED, PHASE 2, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY OF DOSTARLIMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
This study looks at new treatments for a type of lung cancer that has spread. It compares two different drug combinations, both including chemotherapy, to see which works better at shrinking tumours and helping people live longer. It's a key step in finding improved care.
Germany · Romania · Italy - active not recruitingPHASE3
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
This study is looking at a new combination of medicines, belrestotug and dostarlimab, for people with a certain type of lung cancer that hasn't been treated before. It compares this combination to a standard treatment (pembrolizumab) and a dummy drug (placebo).
United States · Argentina · Belgium - active not recruitingPHASE2, PHASE3
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
This study looks at new drug combinations for advanced non-small cell lung cancer that has progressed after standard treatments. It compares adding new medicines, cobolimab and dostarlimab, to docetaxel chemotherapy, to see if they work better together.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
This study looks at new ways to predict how well people with lung cancer might respond to certain treatments. It uses special tests on blood, lab-grown tumour models, and body scans to understand the cancer better and help doctors choose the best treatment.
United Kingdom - active not recruitingPHASE2
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
This study is looking at new combinations of medicines for advanced lung cancer that hasn't been treated before. We want to see how safe these new treatments are and how well they work together. It's for people whose cancer shows high levels of a specific marker called PD-L1.
United States · Argentina · Belgium - recruiting
TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
This study, called TRACERx EVO, looks at how lung cancer and mesothelioma change during treatment. It involves collecting information and samples from patients with early or advanced disease to help doctors understand the illnesses better and find new ways to treat them.
United Kingdom